BE in hepatic impairment? [BE/BA News]

posted by nobody – 2019-08-30 09:29  – Posting: # 20530
Views: 474

Hello again!

Today I have to read this here:

https://www.fdanews.com/articles/192544-persion-petitions-fda-to-raise-the-safety-bar-for-extended-release-opioid

But the originator found differences in PK in mild/moderate hepatic impairment not worth any dose adjustment according to the current label and the differences as outlined in the FDA AssRep are unimpressive. I'm trying to figure out a formulation-related influence of hepatic function on BA/BE...

Lawyers looking for some work? How low can you go? Is that state-of-the-art in 2019?

Kindest regards, nobody

Complete thread:

Activity
 Admin contact
20,236 posts in 4,258 threads, 1,396 registered users;
online 9 (0 registered, 9 guests [including 4 identified bots]).
Forum time (Europe/Vienna): 15:05 CET

You can do one of two things; just shut up,
which is something I don’t find easy,
or learn an awful lot very fast,
which is what I tried to do.    Jane Fonda

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5